KALA BIO, Inc. — Director's Dealing 2020

Jun 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-06-19

Reporting Person: Trachtenberg Eric (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-19	Common Stock	M	28901	$5.19	Acquired	28901	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-19	Stock Option (right to buy)	$5.19	M	28901	Disposed	2029-01-01	Common Stock (28901)	Direct

Footnotes

F1: This option was granted on January 2, 2019 and vests over four years, with 1/48th of the shares underlying the option vesting at the end of each successive one-month period following the date of grant.